Cystic Fibrosis Trwst A starting point for plain language summaries



Minimal function mutation Nasal transepithelial potential difference 3 **Nonsense mutation** Gating mutation 4 Minimal clinically important 5 difference (MCID) **Residual function mutation** 5 Forced expiratory volume (%ppFEV1) **Pulmonary exacerbation** rate (PeX) Medicine washout period 8 **Mucolvtic** 8 **Mucociliary clearance** 8 9 Corrector Potentiator 10 Lung clearance index CFTR modulator Forced vital capacity (FVC) Genotype Amplifier Protein CFTR Anti-inflammatory (Compound) Heterozygous Multiple Breath Washout Sweat chloride CF questionnaire-revised (CFQR) Spirometry Homozygous Six minute walk test (6MWT) Glossarv

Authors: Hilde De Keyser (1), Emmanuelle Bardin (1, 2), Jill Bonjean (1), Fiona Dunlevy (3), Rebecca Brendell (4), Lorna Allen (4). Affiliations: (1) CF Europe, (2) Association Muco, (3) European Cystic Fibrosis Society-Clinical Trials Network, (4) UK Cystic Fibrosis Trust.

Turope

ROTEOSTASIS

1. Context

- Cystic Fibrosis Europe (CFE): federation of national cystic fibrosis (CF) patient organisations in Europe.
- \Rightarrow Defend interests of people with CF, engage with key stakeholders (EU, industry, etc.).
- CF Round Table of Companies (CFRToC): collaboration between CFE and companies (5) active in CF.
- \Rightarrow long-term educational collaboration.
- New European regulation regarding clinical trials (CTs) (536/2014).
- $\Rightarrow \textbf{lay summaries of CT results.} \\\Rightarrow need for improved \\communication tools.$

Overarching aim:

Collaboration between CFE, the Cystic Fibrosis Trust (CFT), the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) and CFRToC to establish a standardised glossary of CF terms, for systematic use in patient-friendly CT summaries

5. Perspectives

⇒ Importance of the targeted audience: definitions for **lay audience without prior knowledge of the illness or related-terms.**

VERTEX

 \Rightarrow Agreement of stakeholders on utilisation of terms and glossary.

2. Objectives of the study

- Select ~10 terms, CF-specific and commonly used in CT to be defined in a pilot study of the glossary.
- Define a workflow with all stakeholders leading to a glossary approved by the participating companies.

3. Methods

Boehringer

Ingelheim

Mylan

CFE, CFT and CTN preselected 27 CF-terms.

NB: Generic CT terms, not specific to CF, defined elsewhere were excluded.

- Patients representatives from *Sweden, Finland, Belgium, Moldova, France, The Netherlands, Israel, Turkey and United Kingdom* were asked to rank the 10-top terms to be defined as a priority in a glossary.
 - The top-ranked terms were validated by industrial partners as a kick-off set

4. Results

- ⇒ Shortlist of 11 terms with the highest ranking by CF patients representatives (see table 1.).
- \Rightarrow Ranking reflects the fact that the voters are familiar with CF vocabulary.
- ⇒ Terms with highest ranks show good variety of terms between clinical research and basic science specific to CF.
- \Rightarrow Approval by participating companies.
- \Rightarrow Creation and publicity of an online glossary.
- \Rightarrow Translation into national languages.